MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug's ...
John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual ...
Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...
Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...
Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...
The nominee for HHS secretary hedged this answers to questions about vaccine safety and efficacy at his second confirmation hearing today.
MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...
A phase 3 trial evaluating sotatercept-csrk (Winrevairâ„¢) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...
The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.
The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...
The FDA upgraded a recall of Lay's classic potato chips in Oregon and Washington to the highest level of severity, warning of potentially serious consequences from eating the product due to undeclared ...